BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18056755)

  • 1. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
    van der Heijde D; Pangan AL; Schiff MH; Braun J; Borofsky M; Torre J; Davis JC; Wong RL; Kupper H; Collantes E;
    Ann Rheum Dis; 2008 Sep; 67(9):1218-21. PubMed ID: 18056755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.
    van der Heijde D; Schiff MH; Sieper J; Kivitz AJ; Wong RL; Kupper H; Dijkmans BA; Mease PJ; Davis JC;
    Ann Rheum Dis; 2009 Jun; 68(6):922-9. PubMed ID: 18701556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
    Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
    Huang F; Gu J; Zhu P; Bao C; Xu J; Xu H; Wu H; Wang G; Shi Q; Andhivarothai N; Anderson J; Pangan AL
    Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion.
    Rudwaleit M; Olivieri I; Boki KA; Griep EN; Järvinen P; Wong RL; Kron M; Kary S; Kupper H
    Rheumatology (Oxford); 2009 May; 48(5):551-7. PubMed ID: 19254918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement.
    Horneff G; Fitter S; Foeldvari I; Minden K; Kuemmerle-Deschner J; Tzaribacev N; Thon A; Borte M; Ganser G; Trauzeddel R; Huppertz HI
    Arthritis Res Ther; 2012 Oct; 14(5):R230. PubMed ID: 23095307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
    Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
    Rudwaleit M; Claudepierre P; Wordsworth P; Cortina EL; Sieper J; Kron M; Carcereri-De-Prati R; Kupper H; Kary S
    J Rheumatol; 2009 Apr; 36(4):801-8. PubMed ID: 19273449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.
    Deodhar A; Reveille JD; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    J Rheumatol; 2018 Mar; 45(3):341-348. PubMed ID: 29247154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.
    Sieper J; van der Heijde D; Dougados M; Brown LS; Lavie F; Pangan AL
    Ann Rheum Dis; 2012 May; 71(5):700-6. PubMed ID: 22128084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
    Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Lambert RG; Salonen D; Rahman P; Inman RD; Wong RL; Einstein SG; Thomson GT; Beaulieu A; Choquette D; Maksymowych WP
    Arthritis Rheum; 2007 Dec; 56(12):4005-14. PubMed ID: 18050198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial.
    Li J; Xue Z; Wu Z; Bi L; Liu H; Wu L; Liu S; Huang X; Wang Y; Zhang Y; Qi W; He L; Dai L; Sun L; Li X; Shuai Z; Zhao Y; Wang Y; Xu J; Zhang H; Yu H; Chen X; Bao C
    Clin Rheumatol; 2022 Oct; 41(10):3005-3016. PubMed ID: 35676450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
    van der Heijde D; Breban M; Halter D; DiVittorio G; Bratt J; Cantini F; Kary S; Pangan AL; Kupper H; Rathmann SS; Sieper J; Mease PJ
    Rheumatology (Oxford); 2015 Jul; 54(7):1210-9. PubMed ID: 25541333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
    van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
    Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of adalimumab versus etanercept in patients with ankylosing spondylitis and total spinal ankylosis in Croatia: a multicentre 12-month follow-up study.
    Grubišić F; Naglić ĐB; Perić P; Morović-Vergles J; Anić B; Kehler T; Novak S; Hanih M; Gračanin AG; Marković NL; Grazio S
    Clin Rheumatol; 2022 Aug; 41(8):2417-2421. PubMed ID: 35434764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
    Deodhar A; Shiff NJ; Gong C; Chan EKH; Hsia EC; Lo KH; Akawung A; Kim L; Xu S; Reveille JD
    Rheumatol Ther; 2023 Aug; 10(4):983-999. PubMed ID: 37322274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.